Publications

Below is a selection of some of published studies reflecting our high-impact work. For a full list of our publications, please visit PubMed.

• Brainstem and cerebellar radiological findings in progressive supranuclear palsy. Brain Communications, 2025. Spiegel, C., Marotta, C., Bertram, K., Vivash, L., Harding, I.H.

• Biomarkers of disease progression in progressive supranuclear palsy for use in clinical trials. Brain Communications, 2025. Marotta, C., Sinclair, B., O’Brien, T.J. & Vivash, L.

• Brain-derived tau to measure treatment effect in Alzheimer's disease and frontotemporal dementia. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2025. Marotta, C., Gonzalez-Ortiz, F., Turton, M., Zetterberg, H., Harrison, P., Hovens, C. M., Sinclair, B., O'Brien, T. J., Blennow, K., & Vivash, L.

• Automated segmentation of epilepsy surgical resection cavities: Comparison of four methods to manual segmentation. Neuroimage 2024 Courtney MR, Sinclair B, Neal A, Nicolo JP, Kwan P, Law M, O'Brien TJ, Vivash L

• Association of Localizing 18F-FDG-PET Hypometabolism and Outcome Following Epilepsy Surgery: Systematic Review and Meta-Analysis. Neurology, 2024 Courtney MR, Antonic-Baker A, Chen Z, Sinclair B, Nicolo JP, Neal A, Marotta C, Bunyamin J, Law M, Kwan P, O'Brien TJ, Vivash L.

• Linking PI-2620 tau-PET, fluid biomarkers, MRI, and cognition to advance diagnostics for progressive supranuclear palsy. medRxiv 2024. Dilcher, R., Malpas, C. B., O’Brien, W. T., McDonald, S. J., Despott, C., Bertram, K., Pase, M. P., Law, M., O’Brien, T. J. & Vivash, L.

• Phase II randomised placebo-controlled trial of sodium selenate as a disease-modifying treatment in chronic drug-resistant temporal lobe epilepsy: the SeLECT study protocol. BMJOpen 2023. Vivash L, Johns H, Churilov L, MacPhail S, Casillas-Espinosa P, Malpas C, Shultz SR, Tailby C, Wijayath M, Reutens D, Gillinder L, Perucca P, Carney P, Nicolo JP, Lawn N, Kwan P, Velakoulis D, Hovens CM, O'Brien TJ.

• A phase 1b open-label study of sodium selenate as a disease-modifying treatment for possible behavioral variant frontotemporal dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2022. Vivash, L., Malpas, C. B., Meletis, C., Gollant, M., Eratne, D., Lin, Q-X., McDonald, S., O'Brien, W. T., Brodtmann, A. G., Darby, D. G., Kyndt, C., Walterfang, M., Hovens, C. M., Velakoulis, D., & O'Brien, T. J.

• Perivascular spaces as a marker of disease severity and neurodegeneration in patients with behavioral variant frontotemporal dementia. Frontiers in Neuroscience, 2022. Moses, J., Sinclair, B., Schwartz, D. L., Silbert, L. C., O’Brien, T. J., Law, M., & Vivash, L.

• Effective Preparation of [18F]Flumazenil Using Copper-Mediated Late-Stage Radiofluorination of a Stannyl Precursor. Molecules, 2022. Haskali, M. B., Roselt, P. D., O'Brien, T. J., Hutton, C. A., Ali, I., Vivash, L., & Jupp, B.

• Sodium selenate as a therapeutic for tauopathies: A hypothesis paper. Frontiers in Aging Neuroscience, 2022. Dilcher, R., Malpas, C. B., Walterfang, M., Velakoulis, D., O’Brien, T. J., & Vivash, L.

• 18F-FDG-PET hypometabolism as a predictor of favourable outcome in epilepsy surgery: protocol for a systematic review and meta-analysis. BMJ Open, 2022. Courtney, M. R., Antonic-Baker, A., Sinclair, B., Nicolo, J. P., Neal, A., Law, M., Kwan, P., O'Brien, T. J., & Vivash, L.

• Development of [18F]MIPS15692, a radiotracer with in vitro proof-of-concept for the imaging of MER tyrosine kinase (MERTK) in neuroinflammatory disease. European Journal of Medicinal Chemistry, 226, 2021. Wong, S. W., Vivash, L., Mudududdla, R., Nguyen, N., Hermans, S. J., Shackleford, D. M., Field, J., Xue, L., Aprico, A., Hancock, N. C., Haskali, M., Stashko, M. A., Frye, S. V., Wang, X., Binder, M. D., Ackermann, U., Parker, M. W., Kilpatrick, T. J., & Baell, J. B.

• Sodium selenate as a disease-modifying treatment for mild-moderate Alzheimer's disease: An open-label extension study. BMJ Neurology Open, 2021. Vivash, L., Malpas, C. B., Hovens, C. M., Brodtmann, A., Collins, S., Macfarlane, S., Velakoulis, D., & O'Brien, T. J

• Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: Protocol for a phase 2, randomised, double-blind, placebo-controlled trial. BMJ Open, 2021. Vivash, L., Bertram, K., Malpas, C. B., Marotta, C., Harding, I., Kolbe, S., Fielding, J., Clough, M., Lewis, S. J. G., Tisch, S., Evans, A. H., O'Sullivan, J. D., Kimber, T. E., Darby, D. G., Churilov, L., Law, M., Hovens, C. M., Velakoulis, D., & O'Brien, T. J.

• Longitudinal changes of focal cortical glucose hypometabolism in adults with chronic drug resistant temporal lobe epilepsy. Brain Imaging and Behavior, 2021. Sharpe, C., Sinclair, B., Kwan, P., Hicks, R. J., O’Brien, T. J., & Vivash, L.

• The effect of injection time on rates of epileptogenic zone localization using SISCOM and STATISCOM.Epilepsy & Behavior, 2021. Hlauschek, G., Sinclair, B., Brinkmann, B., Fuge, J., Kwan, P., O'Brien, T. J., & Vivash, L.